logo

Kalvista Pharmaceuticals, Inc. (KALV)



Trade KALV now with
  Date
  Headline
9/8/2022 7:04:51 AM KalVista Pharma Q1 Net Loss $23.0 Mln Or $0.94/Shr Vs Loss Of $16.1 Mln Or $0.66/Shr Last Year
9/2/2022 7:01:49 AM KalVista Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/7/2022 6:52:26 AM KalVista Pharma Q4 Net Loss $24.1 Mln Or $0.98/Shr Vs Loss Of $15.0 Mln Or $0.65/Shr Last Year
1/4/2022 7:05:48 AM KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/10/2021 6:38:21 AM KalVista Updates On KVD900 For Oral On-Demand Treatment Of Hereditary Angioedema; Finalizes Phase 3 Trial Protocol
9/15/2021 6:16:23 AM KalVista's KOMPLETE View
9/14/2021 6:53:08 AM KalVista: FDA Lifts Clinical Hold On Phase 2 Clinical Trial Of KVD824 For Hereditary Angioedema
8/9/2021 7:17:15 AM KalVista Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/12/2021 7:41:06 AM KalVista Pharma Presents Phase 2 Data For KVD900 At EAACI Congress
5/3/2021 7:15:55 AM KalVista Pharma Appoints Paul Audhya As Chief Medical Officer